Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) FCF Margin: 2017-2025

Historic FCF Margin for Crinetics Pharmaceuticals (CRNX) over the last 5 years, with Sep 2025 value amounting to -78,028.67%.

  • Crinetics Pharmaceuticals' FCF Margin was N/A to -78,028.67% in Q3 2025 from the same period last year, while for Sep 2025 it was -18,304.08%, marking a year-over-year change of. This contributed to the annual value of -22,118.77% for FY2024, which is 1785774.00% down from last year.
  • Crinetics Pharmaceuticals' FCF Margin amounted to -78,028.67% in Q3 2025, which was down 803.37% from -8,637.54% recorded in Q2 2025.
  • Crinetics Pharmaceuticals' FCF Margin's 5-year high stood at -435.32% during Q1 2022, with a 5-year trough of -78,028.67% in Q3 2025.
  • Over the past 3 years, Crinetics Pharmaceuticals' median FCF Margin value was -10,408.87% (recorded in 2024), while the average stood at -18,911.27%.
  • Within the past 5 years, the most significant YoY rise in Crinetics Pharmaceuticals' FCF Margin was 354,266bps (2025), while the steepest drop was 1,637,828bps (2025).
  • Crinetics Pharmaceuticals' FCF Margin (Quarterly) stood at -5,004.37% in 2022, then plummeted by 440,881bps to -12,959.25% in 2023, then tumbled by 752,888bps to -12,180.20% in 2024, then spiked by 354,266bps to -78,028.67% in 2025.
  • Its FCF Margin was -78,028.67% in Q3 2025, compared to -8,637.54% in Q2 2025 and -24,845.15% in Q1 2025.